Signifier Medical Technologies LLC will discuss the use of neuromuscular electrical stimulation to treat obstructive sleep apnea (OSA) during a presentation at the World Sleep 2023 Congress. 

Signified Medical received US Food and Drug Administration (FDA) De Novo authorization for eXciteOSA, a device that delivers neuromuscular stimulation to the tongue to reduce snoring and mild sleep apnea, in 2021.

The World Sleep presentation will be led by doctors Alexandre Abreu, MD; Atul Malhotra, MD; Adrian Williams; Marina Carrasco-Llatas, MD, PhD; and Naresh Punjabi, MD, who will dive into the research and clinical findings that demonstrate the efficacy and benefits of neuromuscular electrical stimulation in treating OSA. At this session, attendees can expect to gain an understanding of the therapy’s mechanism of action, clinical trial results, and its benefits on patient quality of life.

“We look forward to sharing our research and engaging with sleep medicine professionals from around the world at the World Sleep 2023 Congress,” says Punjabi in a release. “By collaborating and exchanging ideas, we can collectively work towards improving the lives of individuals affected by sleep disorders.”

Over 12,000 patients have started eXciteOSA, achieving over 80% therapy adherence, according to a release from Signifier Medical.

“We are thrilled that the importance of [neuromuscular electrical stimulation] to meet the unmet needs of OSA patients is being recognized in a World Sleep session,” says Akhil Tripathi, director and co-founder of Signifier Medical, in a release. “This recognition affirms the significance of our research and the potential of neuromuscular electrical stimulation as a novel and effective approach in treating obstructive sleep apnea.”

The World Sleep 2023 Congress is scheduled for Oct 20-25 in Rio de Janeiro, Brazil. Signifier Medical’s presentation will take place on Tuesday, Oct 24, from 10:45 am to 12:15 pm.